TASO-001 + aldesleukin

TASO-001 + aldesleukin is a **combination therapy** of TASO-001 (also known as OT-101), a first-in-class anti-transforming growth factor-beta 2 (TGF-β2) antisense oligonucleotide, and aldesleukin, a recombinant form of interleukin-2 (IL-2). TASO-001 works by inhibiting TGF-β2, a cytokine involved in tumor immune evasion and progression, while aldesleukin acts as a cytokine therapy that stimulates the proliferation and activation of T cells and natural killer (NK) cells to mount an anti-tumor immune response. The combination is being developed primarily for advanced or metastatic solid tumors, including pancreatic cancer, melanoma, colorectal cancer, and renal cell carcinoma. Clinical trials are evaluating its efficacy, safety, and dose finding, with evidence of synergistic effects that may improve cure rates compared to monotherapy and potential utility as an adjunct to other immunotherapies[1][3][5][7][8].

Brand names

Proleukin

Other names

recombinant interleukin-2 (for aldesleukin)TGF-β2 targeting anti-sense oligonucleotide-001 (for TASO-001)OT-101 (for TASO-001)